This study investigated the beneficial effects of co-administering anti-diabetes medication metformin (Glucophage) and doxorubicin (Adriamycin)-cyclophosphamide (Cytoxan) with paclitaxel (Taxol) (AC-T) chemotherapy in non-diabetic patients with breast cancer (BC). The data showed that metformin reduced the occurrence and severity of toxicities associated with AC-T chemotherapy in patients with BC.

The study evaluated the effectiveness of compression bandages applied with different pressures on the skin and subcutaneous tissue in patients with breast cancer-related lymphedema (BCRL). The study concluded that high-pressure compression bandage was more effective in reducing skin and subcutaneous tissue thickness and inflammation in patients with BCRL. 

The study compared the effectiveness and safety of trastuzumab deruxtecan (TD; Enhertu) with trastuzumab emtansine (TE; Kadcyla) in patients with HER2-positive (HER2+) metastatic breast cancer (BC). The study found that TD was more effective and well-tolerated compared to TE in these patients.

This study evaluated the optimal treatment regimens given before and after surgery in terms of improving the survival outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC). The data showed that chemotherapy plus trastuzumab (Herceptin) and pertuzumab (Perjeta) was the best treatment regimen for improving the survival rates of these patients.

This study evaluated the effectiveness and safety of oral paclitaxel (Taxol) plus encequidar (HM 30181) versus intravenous (IV) paclitaxel in patients with metastatic breast cancer (BC). This study concluded that oral paclitaxel plus encequidar was more effective than IV paclitaxel with manageable side effects in these patients.

This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly increased the risk of irregular heartbeat and hypertension (high blood pressure).

This study evaluated the effects of aquatic physical therapy on improvement in fatigue symptoms and quality of life (QoL) in patients with breast cancer (BC). The data showed that aquatic physical therapy reduced fatigue symptoms and improved the QoL in women with BC.

This study evaluated the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer. The data showed that most patients with breast and gynecological cancer developed antibodies after the second dose of the vaccine. However, the authors suggested that for non-responders or weak responders, additional immunization booster seems to be required, along with proactive planning in the vaccination schedule, with vaccine administration spaced out over time with respect to chemotherapy.

The study evaluated the effectiveness of massage therapy for chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast and gastrointestinal (GI) cancer. The main finding of the study was that intensive massage therapy 3 times a week showed promising results in these patients. 

The study evaluated the effectiveness of three exercise programs in improving quality of life (QOL), pain, and lymphedema among breast cancer (BC) survivors. The study found that joint mobility exercise (JME) combined with progressive resistance exercise (PRE) showed promising results in improving QOL and lymphedema after BC surgery.